Scaling Next-Gen Molecules: Why Process Efficiency & Expertise Outweigh Capacity

By Uday Hardikar, SPV & Site Head of Abzena’s Bristol, PA Bioconjugate Development & Manufacturing facility

While facility capacity is often prioritized in biopharmaceutical manufacturing, process efficiency and operational expertise are far more critical for long-term commercial readiness. Expanding physical footprint alone frequently fails to resolve common bottlenecks such as communication silos, slow technology transfers, and reactive problem-solving. Adopting an engineering-led, cross-functional approach from the outset ensures that infrastructure, analytics, and manufacturing workflows are harmonized to handle complex modalities like antibody-drug conjugates. By integrating scientific and technical teams early, organizations can streamline batch transitions, maintain stringent quality control, and prevent costly delays. Evaluating potential partners based on structural integration, technical depth, and robust governance models is essential for turning complex scientific innovations into reliable commercial supplies.

Explore the full white paper to discover key strategies for optimizing your next-generation manufacturing programs.